PEG10 Antibody

What is PEG10 and why are antibodies against it important for research?

PEG10 (paternally expressed gene 10) is a retrotransposon-derived gene that contains Gag and Pol-like domains similar to retroviruses. PEG10 is essential for placental development, with knockout mice exhibiting early embryonic lethality due to placental defects . PEG10 antibodies are critical research tools because:

• They enable detection of both PEG10-RF1 (Gag domain) and PEG10-RF1/2 (fusion of Gag and Pol domains) protein forms

• They facilitate investigation of PEG10's roles in normal development and disease states

• They allow examination of PEG10's unique ability to form virus-like particles (VLPs)

• They support research on PEG10's overexpression in cancers such as hepatocellular carcinoma

What molecular weights should I expect when detecting PEG10 with antibodies?

PEG10 protein detection often reveals discrepancies between calculated and observed molecular weights:

These discrepancies result from post-translational modifications, proteolytic processing, and the -1 frameshift translation mechanism that produces both PEG10-RF1 and PEG10-RF1/2 forms . When analyzing Western blots, be prepared to observe multiple bands representing these different forms and fragments.

Which experimental models are suitable for studying PEG10 expression?

Based on validated reactivity data from multiple antibody sources, the following experimental models are recommended:

Trophoblast stem cells (TSCs) are particularly valuable for studying PEG10's role in placental development, as PEG10-deficient TSCs exhibit impaired differentiation into placental lineages .

How should I optimize Western blot protocols for PEG10 detection?

For optimal Western blot detection of PEG10:

• Sample preparation:

  • Use RIPA buffer with protease inhibitors for cell/tissue lysis

  • Include phosphatase inhibitors if studying phosphorylated forms of PEG10

  • Heat samples at 95°C for 5 minutes in Laemmli buffer with reducing agent

• Gel electrophoresis and transfer:

  • Use 8-10% SDS-PAGE gels to effectively resolve the 50-110 kDa range

  • Transfer proteins to PVDF membranes (preferred over nitrocellulose for PEG10)

• Antibody incubation:

  • Use recommended dilutions: 1:500-1:3000 depending on the antibody

  • Incubate primary antibody overnight at 4°C for optimal signal-to-noise ratio

  • Include positive controls (HepG2 cells, mouse liver tissue)

• Detection considerations:

  • Be prepared to observe multiple bands (50-110 kDa range)

  • Extended exposure times may be necessary for detecting lower abundance forms

This approach has been validated for detecting both PEG10-RF1 and PEG10-RF1/2 in various cell and tissue types .

What are the optimal conditions for immunohistochemical detection of PEG10?

For successful immunohistochemistry (IHC) detection of PEG10:

• Tissue preparation:

  • Formalin-fixed, paraffin-embedded (FFPE) sections (4-6 μm thickness)

  • Antigen retrieval is critical: use TE buffer pH 9.0 (preferred) or citrate buffer pH 6.0

  • Heat-induced epitope retrieval (HIER) at 95-100°C for 15-20 minutes yields best results

• Antibody application:

  • Recommended dilutions range from 1:50-1:2000 depending on the antibody

  • Validated positive controls include mouse skin tissue and human placenta

  • Overnight incubation at 4°C often yields more specific staining than shorter protocols

• Signal development:

  • DAB (3,3'-diaminobenzidine) substrate works well for PEG10 detection

  • Counterstain with hematoxylin to visualize tissue architecture

This methodology has been successfully applied to detect PEG10 in placental tissues where it plays essential developmental roles .

What approaches are most effective for immunofluorescence detection of PEG10?

For optimal immunofluorescence (IF) staining of PEG10:

• Cell preparation:

  • HeLa cells serve as a validated positive control for IF staining

  • Fix cells with 4% paraformaldehyde for 15 minutes at room temperature

  • Permeabilize with 0.2% Triton X-100 for 10 minutes

• Antibody incubation:

  • Use recommended dilutions: 1:200-1:800 for most PEG10 antibodies

  • Block with 5% normal serum (matching secondary antibody host) with 1% BSA

  • Incubate primary antibody overnight at 4°C for best results

• Subcellular localization considerations:

  • PEG10 can be detected in cytoplasmic, perinuclear, and vesicular patterns

  • For co-localization studies, combine with markers for stress granules or extracellular vesicles

  • Nuclear counterstaining with DAPI helps contextualize PEG10 localization

This approach has been validated for studying PEG10's subcellular distribution and its role in forming extracellular vesicles .

How can I investigate PEG10's role in virus-like particle (VLP) formation?

PEG10 can assemble into virus-like particles (VLPs) that are released as extracellular vesicles . To study this function:

• Experimental design for VLP isolation:

  • Transfect HEK293T cells with PEG10 expression constructs

  • Collect culture supernatant after 48-72 hours

  • Perform differential ultracentrifugation to isolate VLPs

  • For higher purity, use sucrose gradient centrifugation (note: PEG10 VLPs are denser than HIV-1 p24 VLPs)

• VLP analysis methods:

  • Western blot: probe for PEG10 in both cell lysates and purified VLP fractions

  • Electron microscopy: use immuno-gold labeling with PEG10 antibodies to confirm VLP identity

  • Protease protection assay: treat VLPs with trypsin with/without Triton X-100 to confirm membrane encapsulation

• Functional verification:

  • RNA content analysis: RT-PCR or RNA-seq of VLP contents

  • Transfer experiments: label VLPs and track uptake by recipient cells

This methodology has revealed that PEG10's Gag domain supports VLP assembly similar to HIV p24 Gag protein, and these particles can be utilized for intercellular communication .

How can I study the interaction between PEG10 and RTL8?

Recent research has identified RTL8 as an antagonist of PEG10-mediated VLP formation . To investigate this interaction:

• Protein-protein interaction analysis:

  • Co-immunoprecipitation: Immunoprecipitate PEG10 and probe for RTL8 co-precipitation

  • Use crosslinking reagents to stabilize transient interactions

  • The interaction specifically involves the N-terminal lobe of the PEG10 capsid domain

• Domain mapping experiments:

  • Generate constructs expressing different domains of PEG10 (full-length, gag, capsid NTD, capsid CTD)

  • Co-express with RTL8 and perform co-immunoprecipitation

  • As shown in existing research, RTL8 interacts with PEG10 gag and capsid NTD but not capsid CTD

• Functional assessment:

  • Measure VLP release by quantifying PEG10 in cell lysates versus conditioned media

  • Co-transfect varying amounts of RTL8 with constant PEG10 to establish dose-dependence

  • Use cell lines with differential RTL8 expression to correlate with PEG10 VLP release capacity

This approach has demonstrated that RTL8 incorporates into PEG10 VLPs, binds to the PEG10 N-terminal lobe, and is associated with increased intracellular PEG10 levels and reduced VLP release .

How can I employ PEG10 in engineering neoantigen delivery systems?

Recent advances have utilized PEG10's ability to form VLPs for vaccine development and antigen delivery . To explore this application:

• Engineering PEG10-based antigen carriers:

  • Design fusion constructs linking PEG10 gag domain with antigens of interest

  • Transfect HEK293T cells and isolate endogenous virus-like particles (eVLPs)

  • Quantify protein yield (studies show ~212±7.388 μg per 10 cm dish compared to 76.59±7.463 μg for controls)

• Surface modification for enhanced targeting:

  • Modify eVLPs with targeting moieties like CpG-ODN to enhance DC targeting

  • DBCO-C6-NHS ester can be used to anchor moieties to eVLPs

  • Verify modification by agarose gel electrophoresis and flow cytometry

• Functional validation:

  • Measure antigen presentation by dendritic cells

  • Assess T cell activation in response to presented antigens

  • In vivo tracking of particle distribution (particularly to lymph nodes)

This methodology has successfully produced PEG10-based neoantigen delivery systems (termed ePAC) that effectively activate immune responses against liver cancer in mouse models .

How can I resolve detection issues when working with PEG10 antibodies?

Common issues with PEG10 detection and their solutions include:

• Multiple or unexpected bands in Western blots:

  • Cause: PEG10 exists in multiple forms (RF1, RF1/2, cleaved products)

  • Solution: Use positive controls (HepG2 cells) to establish expected banding patterns

  • Validation: The calculated MW is 80 kDa, but observed MWs include 50-60 kDa and 100-110 kDa bands

• Weak or absent signal:

  • Cause: Low expression levels in certain tissues/cells or suboptimal antibody dilution

  • Solution: Enrich samples through immunoprecipitation before Western blotting

  • Validation: PEG10 expression varies significantly between tissues; placental and cancer tissues show higher expression

• Non-specific background in immunostaining:

  • Cause: Insufficient blocking or cross-reactivity

  • Solution: Extend blocking time (2+ hours), try alternative blocking agents (5% BSA, protein-free blockers)

  • Validation: Comparison with isotype controls can help identify non-specific binding

• Inconsistent results between applications:

  • Cause: Different epitope accessibility in various applications

  • Solution: Test multiple antibodies targeting different regions of PEG10

  • Validation: Some antibodies work better for specific applications (e.g., 14412-1-AP shows strong results in WB, IHC, and IF)

Proper experimental design with appropriate controls is essential for accurate interpretation of PEG10 detection results.

What are the critical considerations for studying PEG10 in developmental contexts?

When investigating PEG10's role in development, particularly placentation:

• Temporal expression patterns:

  • PEG10 expression increases during trophoblast stem cell (TSC) differentiation

  • Different protein isoforms may predominate at different developmental stages

  • Use time-course analyses to capture dynamic expression changes

• Specialized models:

  • Trophoblast stem cell (TSC) differentiation models

  • Conditional knockout approaches (complete knockouts are embryonic lethal)

  • PEG10 aspartic protease domain mutants show later-onset phenotypes compared to complete knockouts

• Multi-omics approach:

  • Combine analysis of PEG10 protein expression (antibody-based) with RNA analysis

  • Phosphoproteomics has revealed important phosphorylation sites within PEG10

  • Global proteome analysis in PEG10-deficient vs. wild-type cells shows altered phosphorylation of key signaling proteins like MAPK1, MAPK3, MTOR, INSR, and EGFR

This multi-faceted approach has revealed that PEG10 is not only essential for early placenta formation but also for placental vasculature maintenance from mid- to late-gestation .

How should I validate a new PEG10 antibody for my specific application?

Rigorous validation of PEG10 antibodies is essential due to the protein's multiple forms and complex biology:

• Specificity validation:

  • Positive controls: Use HepG2 cells, L02 cells, or mouse liver tissue (known to express PEG10)

  • Negative controls: Include tissues from PEG10 knockout models or siRNA knockdown samples

  • Peptide competition: Pre-incubate antibody with immunizing peptide to confirm specificity

• Application-specific validation:

  • Western blot: Look for expected bands at 50-60 kDa and 100-110 kDa

  • IHC: Confirm appropriate subcellular localization pattern

  • IF: Verify co-localization with known PEG10-interacting proteins or structures

• Cross-antibody validation:

  • Compare results from different antibodies targeting distinct PEG10 epitopes

  • Antibodies targeting the N-terminal region versus the C-terminal region may yield different results

  • For example, antibodies directed against amino acids 1-325 versus those targeting regions beyond amino acid 600 may detect different subsets of PEG10 forms

This validation approach ensures reliable and reproducible results when using PEG10 antibodies for experimental applications.

How can PEG10 antibodies contribute to cancer biomarker research?

PEG10 is overexpressed in multiple cancer types, particularly hepatocellular carcinoma, making it a potential biomarker:

• Immunohistochemical evaluation:

  • Use validated PEG10 antibodies at 1:50-1:200 dilution on FFPE cancer tissues

  • Compare expression levels between tumor and adjacent normal tissues

  • Correlate expression with clinical parameters (tumor stage, recurrence, survival)

• Liquid biopsy applications:

  • Detect PEG10 proteins or PEG10-containing VLPs in patient serum

  • Develop sensitive ELISAs using capture and detection antibody pairs

  • Multiple antibodies targeting different PEG10 epitopes can enhance specificity

• Therapeutic response monitoring:

  • Assess changes in PEG10 expression levels before and after treatment

  • In animal models, PEG10-based cancer vaccines have shown efficacy in hepatocellular carcinoma

Recent research has demonstrated that personalized neoantigen vaccines based on PEG10 technology can effectively prevent recurrence of primary liver cancer after surgery , highlighting the importance of PEG10 antibodies in both diagnostic and therapeutic contexts.

What are the key considerations for studying PEG10's RNA binding properties?

PEG10 has been found to bind its own mRNA and potentially regulate other RNAs, particularly in placental development :

• RNA immunoprecipitation (RIP) protocol:

  • Crosslink cells with formaldehyde to preserve RNA-protein interactions

  • Lyse cells and immunoprecipitate with PEG10 antibodies

  • Extract and analyze bound RNAs by RT-PCR or RNA sequencing

• Target RNA identification:

  • PEG10 binds its own mRNA in specific regions: the 5'-UTR, the boundary between nucleocapsid and protease coding sequences, and the beginning of the 3'-UTR

  • In placental development, PEG10 has been found to bind mRNAs like Hbegf (Heparin-binding EGF-like growth factor)

• Functional validation:

  • Compare RNA levels in wild-type versus PEG10-deficient cells

  • For example, expression of Hbegf is reduced in PEG10-deficient trophoblast stem cells

  • Consider RNA stability assays following actinomycin D treatment

This methodological approach has revealed PEG10's role in binding and potentially stabilizing RNAs that are critical for normal placental development .